公开(公告)号：US07253281B2

公开(公告)日：2007-08-07

申请号：US11169079

申请日：2005-06-28

Applicant: Jonathan Mark Bentley ,  Paul Hebeisen ,  Patrizio Mattei ,  Marc Muller ,  Hans Richter ,  Stephan Roever ,  Sven Taylor

Inventor： Jonathan Mark Bentley ,  Paul Hebeisen ,  Patrizio Mattei ,  Marc Muller ,  Hans Richter ,  Stephan Roever ,  Sven Taylor

IPC: C07D487/04 ,  A61K31/4985

CPC classification number: C07D487/04

Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.

Abstract translation: 本发明涉及1,2,3,4,10,10a，六氢吡嗪并[1,2-a]吲哚衍生物及其药学上可接受的盐，溶剂合物和酯，其中R 1〜 具有权利要求1给出的含义以药物制剂的形式用于治疗或预防中枢神经系统病症，对中枢神经系统的损害，心血管疾病，胃肠道 疾病，尿崩症，肥胖和睡眠呼吸暂停。

公开(公告)号：US07253197B2

公开(公告)日：2007-08-07

申请号：US10634431

申请日：2003-08-05

Applicant: Wolfgang Guba ,  Patrizio Mattei ,  Werner Neidhart ,  Matthias Heinrich Nettekoven ,  Philippe Pflieger

Inventor： Wolfgang Guba ,  Patrizio Mattei ,  Werner Neidhart ,  Matthias Heinrich Nettekoven ,  Philippe Pflieger

IPC: A61K31/426 ,  A61K31/427 ,  C07D277/42 ,  C07D401/12

CPC classification number: C07D417/06 ,  C07D277/42 ,  C07D417/12 ,  C07D417/14

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in the specification, and the compounds, salts and esters can be used for the treatment of obesity.

Abstract translation: 式I化合物及其药学上可接受的盐和酯，其中R 1至R 4具有说明书中给出的含义，并且化合物，盐和酯可以 用于治疗肥胖。

公开(公告)号：US20070106076A1

公开(公告)日：2007-05-10

申请号：US11649132

申请日：2007-01-03

Applicant: Jonathan Bentley ,  Paul Hebeisen ,  Patrizio Mattei ,  Marc Muller ,  Hans Richter ,  Stephan Roever ,  Sven Taylor

Inventor： Jonathan Bentley ,  Paul Hebeisen ,  Patrizio Mattei ,  Marc Muller ,  Hans Richter ,  Stephan Roever ,  Sven Taylor

IPC: C07D487/04 ,  A61K31/498

CPC classification number: C07D487/04

Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a] indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.

Abstract translation: 本发明涉及1,2,3,4,10,10a，六氢吡嗪并[1,2-a]吲哚衍生物及其药学上可接受的盐，溶剂合物和酯，其中R 1〜 具有权利要求1给出的含义以药物制剂的形式用于治疗或预防中枢神经系统病症，对中枢神经系统的损害，心血管疾病，胃肠道 疾病，尿崩症，肥胖和睡眠呼吸暂停。

公开(公告)号：US07166589B2

公开(公告)日：2007-01-23

申请号：US11376976

申请日：2006-03-16

Applicant: Michael G. Klug ,  Patrizio Mattei ,  Werner Mueller ,  Werner Neidhart ,  Matthias Heinrich Nettekoven ,  Philippe Pflieger ,  Jean-Marc Plancher

Inventor： Michael G. Klug ,  Patrizio Mattei ,  Werner Mueller ,  Werner Neidhart ,  Matthias Heinrich Nettekoven ,  Philippe Pflieger ,  Jean-Marc Plancher

IPC: C07D403/04 ,  C07D403/14 ,  A61K31/551 ,  A61P3/04

CPC classification number: C07D401/04 ,  C04B35/632 ,  C07D215/42 ,  C07D401/12 ,  C07D405/14

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract translation: 式I化合物及其药学上可接受的盐和酯，其中R 1，R 2，R 3，A 1， 具有权利要求1给出的意义的化合物可以以用于治疗或预防关节炎，心血管疾病，糖尿病，肾功能衰竭，饮食失调的药物制剂的形式使用， 肥胖。

公开(公告)号：US07122555B2

公开(公告)日：2006-10-17

申请号：US10870580

申请日：2004-06-17

Applicant: Markus Boehringer ,  Bernd Kuhn ,  Patrizio Mattei ,  Robert Narquizian

Inventor： Markus Boehringer ,  Bernd Kuhn ,  Patrizio Mattei ,  Robert Narquizian

IPC: A01N43/42 ,  A61K31/44 ,  C07D455/06 ,  C07D455/00 ,  C07D453/00

CPC classification number: C07D471/04 ,  A61K9/0019 ,  A61K9/1623 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4875

Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as indicated in the description, or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

Abstract translation: 本发明提供式（I）的化合物，其中R 1，R 2，R 3和R 4， 如说明书中所示，或其药学上可接受的盐。 该化合物可用于治疗与DPP-IV相关的疾病，例如糖尿病，特别是非胰​​岛素依赖型糖尿病，以及葡萄糖耐量降低。

公开(公告)号：US20060135512A1

公开(公告)日：2006-06-22

申请号：US11302067

申请日：2005-12-13

Applicant: Markus Boehringer ,  Daniel Hunziker ,  Bernd Kuhn ,  Bernd Loeffler ,  Hans Marty ,  Patrizio Mattei ,  Robert Narquizian

Inventor： Markus Boehringer ,  Daniel Hunziker ,  Bernd Kuhn ,  Bernd Loeffler ,  Hans Marty ,  Patrizio Mattei ,  Robert Narquizian

IPC: A61K31/54 ,  A61K31/445 ,  A61K31/4015 ,  A61K31/135

CPC classification number: C07C211/35 ,  C07D207/27 ,  C07D207/325

Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

Abstract translation: 本发明涉及其中R 1如说明书和权利要求书中所定义的式（I）化合物及其药学上可接受的盐。 所述化合物可用于治疗和/或预防与DPP-IV相关的疾病，例如糖尿病，特别是非胰​​岛素依赖性糖尿病和葡萄糖耐量异常。

公开(公告)号：US07064134B2

公开(公告)日：2006-06-20

申请号：US11272207

申请日：2005-11-10

Applicant: Michael G. Klug ,  Patrizio Mattei ,  Werner Mueller ,  Werner Neidhart ,  Matthias Heinrich Nettekoven ,  Philippe Pflieger ,  Jean-Marc Plancher

Inventor： Michael G. Klug ,  Patrizio Mattei ,  Werner Mueller ,  Werner Neidhart ,  Matthias Heinrich Nettekoven ,  Philippe Pflieger ,  Jean-Marc Plancher

IPC: C07D401/04 ,  C07D401/14 ,  A61K31/4709 ,  A61P3/04

CPC classification number: C07D401/04 ,  C04B35/632 ,  C07D215/42 ,  C07D401/12 ,  C07D405/14

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

公开(公告)号：US06657060B2

公开(公告)日：2003-12-02

申请号：US10008166

申请日：2001-11-08

Applicant: Volker Breu ,  Frank Dautzenberg ,  Patrizio Mattei ,  Werner Neidhart ,  Philippe Pflieger

Inventor： Volker Breu ,  Frank Dautzenberg ,  Patrizio Mattei ,  Werner Neidhart ,  Philippe Pflieger

IPC: C07D40304

CPC classification number: C07D239/42 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06

Abstract: Pyrimidine derivatives have been found to be useful as neuropeptide Y receptor ligands and particularly as antagonists. These pyrimidine derivatives may be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, diabetes, eating disorders, and obesity.